- Home
- RETO vs ATHA Comparison
RETO vs ATHA Comparison
Compare RETO & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- ATHA
- Stock Information
- Founded
- RETO 1999
- ATHA 2011
- Country
- RETO China
- ATHA United States
- Employees
- RETO N/A
- ATHA N/A
- Industry
- RETO Multi-Sector Companies
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- RETO Consumer Discretionary
- ATHA Health Care
- Exchange
- RETO Nasdaq
- ATHA Nasdaq
- Market Cap
- RETO 19.9M
- ATHA 21.0M
- IPO Year
- RETO 2017
- ATHA 2020
- Fundamental
- Price
- RETO $0.91
- ATHA $0.53
- Analyst Decision
- RETO
- ATHA Buy
- Analyst Count
- RETO 0
- ATHA 4
- Target Price
- RETO N/A
- ATHA $11.25
- AVG Volume (30 Days)
- RETO 16.2K
- ATHA 235.4K
- Earning Date
- RETO 10-28-2024
- ATHA 02-20-2025
- Dividend Yield
- RETO N/A
- ATHA N/A
- EPS Growth
- RETO N/A
- ATHA N/A
- EPS
- RETO N/A
- ATHA N/A
- Revenue
- RETO $3,841,142.00
- ATHA N/A
- Revenue This Year
- RETO N/A
- ATHA N/A
- Revenue Next Year
- RETO N/A
- ATHA N/A
- P/E Ratio
- RETO N/A
- ATHA N/A
- Revenue Growth
- RETO N/A
- ATHA N/A
- 52 Week Low
- RETO $0.84
- ATHA $0.41
- 52 Week High
- RETO $5.00
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- RETO 47.58
- ATHA 41.88
- Support Level
- RETO $0.84
- ATHA $0.52
- Resistance Level
- RETO $0.92
- ATHA $0.57
- Average True Range (ATR)
- RETO 0.05
- ATHA 0.04
- MACD
- RETO 0.00
- ATHA -0.00
- Stochastic Oscillator
- RETO 64.60
- ATHA 11.82
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly-ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation and construction of urban ecological environments for capturing, controlling and re-using rainwater. It operates through four segments namely Machinery and Equipment sales, Construction materials sales, Municipal Construction Projects, and Technology Consulting and other services. The company earns its revenue from Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.